1. Pink Sheet

European Notebook: All Change In The C-Suites; EMA PRIME Starts; French Experts Recommend Phase I Changes

 
• By John Davis

Once-in-a-decade leadership changes stack up in Europe’s big pharma companies as the region aims for quicker and more certain drug development, although following a recent fatality an expert committee is advising caution during dose-escalation in Phase I studies.

March has seen the latest CEO change announced at yet another of Europe's big pharma companies, with the announcement that GlaxoSmithKline PLC’s CEO Andrew Witty is to retire in Mar. 2017.

The move adds to the previously announced retirement of Bayer AG's chief executive Marijn Dekkers, the appointment of Stefan...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography